居家新冠检测的使用——美国,2021年8月23日至2022年3月12日
基于美国≥18岁成人横断面非概率在线调查(2021年8月23日至2022年3月12日),自报有新冠样 illness 的受访者中居家检测使用率从 Delta 主导期 5.7% 升至 Omicron 主导期 20.1%。检测原因以新冠暴露(39.4%)和新冠样症状(28.9%)最常见,使用率随种族、年龄、家庭收入、教育程度和地理区域而异。
要点
- 自报新冠样 illness 者居家检测使用率从 Delta 期 5.7% 升至 Omicron 期 20.1%。
- 居家检测最常见原因为新冠暴露(39.4%)和新冠样症状(28.9%)。
- 使用率存在种族、年龄、收入、教育和地理差异。
核心结论
- 居家新冠检测使用增加可能使实验室报告系统低估实际感染发生率;为检测可及性有限的服务不足人群提供可靠、低成本或免费居家检测试剂盒可能有助于持续预防工作。
研究设计与样本
- 横断面、非概率在线调查,纳入美国≥18岁成人,调查时间为2021年8月23日至2022年3月12日,用于估计自报居家检测使用随时间及按人口学、地理、症状/综合征和检测原因的变化。
主要发现
- 自报新冠样 illness 的受访者中,居家检测使用率从 Delta 主导期(2021年8月23日至12月11日)5.7% 升至 Omicron 主导期(2021年12月19日至2022年3月12日)20.1%。
- 使用居家检测者报告检测原因最常见为新冠暴露(39.4%)和新冠样症状(28.9%)。
- 居家检测使用率按种族:自认白人 5.9% vs 自认黑人 2.8%。
- 居家检测使用率按年龄:30-39岁成人 6.4% vs ≥75岁成人 3.6%。
- 居家检测使用率按家庭收入:>$150,000 9.5% vs $50,000-$74,999 4.7%;按教育:研究生学位 8.4% vs 高中或以下 3.5%;按地理:新英格兰分区 9.6% vs 西中南部分区 3.7%。
临床怎么用
- 新冠检测(包括居家检测)连同隔离检疫、阳性检测或已知暴露后按建议佩戴贴合良好的口罩以及及时接种疫苗等预防措施,可帮助减少新冠传播。
- 为检测可及性有限的服务不足人群提供可靠、低成本或免费居家检测试剂盒可能有助于持续预防工作。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 testing provides information regarding exposure and transmission risks, guides preventative measures (e.g., if and when to start and end isolation and quarantine), identifies opportunities for appropriate treatments, and helps assess disease prevalence (1). At-home rapid COVID-19 antigen tests (at-home tests) are a convenient and accessible alternative to laboratory-based diagnostic nucleic acid amplification tests (NAATs) for SARS-CoV-2, the virus that causes COVID-19 (2-4). With the emergence of the SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants in 2021, demand for at-home tests increased† (5). At-home tests are commonly used for school- or employer-mandated testing and for confirmation of SARS-CoV-2 infection in a COVID-19-like illness or following exposure (6). Mandated COVID-19 reporting requirements omit at-home tests, and there are no standard processes for test takers or manufacturers to share results with appropriate health officials (2). Therefore, with increased COVID-19 at-home test use, laboratory-based reporting systems might increasingly underreport the actual incidence of infection. Data from a cross-sectional, nonprobability-based online survey (August 23, 2021-March 12, 2022) of U.S. adults aged ≥18 years were used to estimate self-reported at-home test use over time, and by demographic characteristics, geography, symptoms/syndromes, and reasons for testing. From the Delta-predominant period (August 23-December 11, 2021) to the Omicron-predominant period (December 19, 2021-March 12, 2022)§ (7), at-home test use among respondents with self-reported COVID-19-like illness¶ more than tripled from 5.7% to 20.1%. The two most commonly reported reasons for testing among persons who used an at-home test were COVID-19 exposure (39.4%) and COVID-19-like symptoms (28.9%). At-home test use differed by race (e.g., self-identified as White [5.9%] versus self-identified as Black [2.8%]), age (adults aged 30-39 years [6.4%] versus adults aged ≥75 years [3.6%]), household income (>$150,000 [9.5%] versus $50,000-$74,999 [4.7%]), education (postgraduate degree [8.4%] versus high school or less [3.5%]), and geography (New England division [9.6%] versus West South Central division [3.7%]). COVID-19 testing, including at-home tests, along with prevention measures, such as quarantine and isolation when warranted, wearing a well-fitted mask when recommended after a positive test or known exposure, and staying up to date with vaccination,** can help reduce the spread of COVID-19. Further, providing reliable and low-cost or free at-home test kits to underserved populations with otherwise limited access to COVID-19 testing could assist with continued prevention efforts.
引用
- Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests - United States, August 23, 2021-March 12, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35358168. doi:10.15585/mmwr.mm7113e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。